Organon Quarterly Income Statement
NYSE: OGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Organon revenue and earnings
In the quarter ended Jun 30, 2026, Organon generated $1.56 billion in revenue, down 2.3% from the same quarter a year earlier. Net income was $108.0 million (-25.5% year over year), for a net margin of 6.9% versus a median of 9.1% in the prior 5 quarters. Gross margin was 54.4% (down from 54.8%).
Diluted earnings per share came in at $0.40, down from $0.56.
Summary generated from market data by MetaCap's automated system. Methodology
Organon income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.56B | 1.46B | 1.51B | 1.60B | 1.59B | 1.51B | 1.59B | 1.58B | 1.61B | 1.62B | 1.60B | 1.52B |
| Revenue growth (YoY) | -2.26% | -3.50% | -5.34% | +1.26% | -0.81% | -6.72% | -0.38% | +4.15% | -0.06% | +5.46% | +7.61% | -1.17% |
| Cost of Revenue | 711.00M | 677.00M | 766.00M | 745.00M | 720.00M | 672.00M | 696.00M | 659.00M | 668.00M | 665.00M | 683.00M | 612.00M |
| Gross Profit | 847.00M | 783.00M | 741.00M | 857.00M | 874.00M | 841.00M | 896.00M | 923.00M | 939.00M | 957.00M | 915.00M | 907.00M |
| Research & Development | 90.00M | 93.00M | 91.00M | 84.00M | 95.00M | 96.00M | 130.00M | 111.00M | 116.00M | 112.00M | 134.00M | 137.00M |
| Selling, General & Admin | 434.00M | 424.00M | 433.00M | 415.00M | 453.00M | 420.00M | 470.00M | 422.00M | 437.00M | 431.00M | 469.00M | 538.00M |
| Interest Expense | 108.00M | 111.00M | 121.00M | 128.00M | 131.00M | 124.00M | 132.00M | 126.00M | 131.00M | 131.00M | 129.00M | 134.00M |
| Pretax Income | 183.00M | 213.00M | -148.00M | 243.00M | 229.00M | 101.00M | 129.00M | 207.00M | 235.00M | 236.00M | 104.00M | 80.00M |
| Income Tax | 75.00M | 67.00M | 57.00M | 83.00M | 84.00M | 14.00M | 20.00M | -152.00M | 40.00M | 35.00M | -442.00M | 22.00M |
| Net Income | 108.00M | 146.00M | -205.00M | 160.00M | 145.00M | 87.00M | 109.00M | 359.00M | 195.00M | 201.00M | 546.00M | 58.00M |
| Net Income growth (YoY) | -25.52% | +67.82% | -288.07% | -55.43% | -25.64% | -56.72% | -80.04% | +518.97% | -19.42% | +13.56% | +405.56% | -74.45% |
| EPS (Basic) | 0.41 | 0.56 | -0.79 | 0.61 | 0.56 | 0.34 | 0.43 | 1.39 | 0.76 | 0.78 | 2.13 | 0.23 |
| EPS (Diluted) | 0.40 | 0.55 | -0.78 | 0.61 | 0.56 | 0.33 | 0.42 | 1.38 | 0.75 | 0.78 | 2.12 | 0.23 |
| Shares Outstanding (Basic) | 262.61M | 260.37M | — | 259.98M | 259.94M | 257.86M | — | 257.50M | 257.29M | 255.69M | — | 255.59M |
| Shares Outstanding (Diluted) | 270.45M | 262.90M | — | 260.65M | 260.16M | 261.00M | — | 259.76M | 258.60M | 258.36M | — | 256.35M |
| Gross Margin | 54.36% | 53.63% | 49.17% | 53.50% | 54.83% | 55.58% | 56.28% | 58.34% | 58.43% | 59.00% | 57.26% | 59.71% |
| Net Margin | 6.93% | 10.00% | -13.60% | 9.99% | 9.10% | 5.75% | 6.85% | 22.69% | 12.13% | 12.39% | 34.17% | 3.82% |
This table shows 12 quarterly periods of Organon's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow OGN's reporting calendar. What is a income statement?